Multiple Myeloma is a cancer of plasma cells associated with significantly reduced survival. Long term survivorship from myeloma is very rare and despite advances in its treatment the disease is generally considered incurable. We report a patient diagnosed with myeloma carrying a germline mutation of a tumour suppressor gene who has effectively been cured.
A 36-year-old woman was diagnosed with IgG lambda myeloma in 1985. She was treated with melphalan chemotherapy followed by high-dose melphalan and autologous stem cell rescue and since remained in complete remission despite not having received any additional therapy. After eliciting a prior history of multiple primary melanomas and breast cancer, she was tested for and shown to be a carrier for a germline mutation in CDKN2A.
This is the second case report of germline mutation of CDKN2A being associated with myeloma. CDKN2A is a stabiliser of p53. Long term survivorship after high dose DNA damaging chemotherapy with melphalan in this patient is compatible with an increased chemo-sensitivity due to impairment of the DNA repair pathway.
Dilworth D, et al. Germline CDKN2A mutation implicated in predisposition to multiple myeloma. Blood. 2000;95(5):1869–71. PubMed
Borg A, et al. Novel germline p16 mutation in familial malignant melanoma in southern Sweden. Cancer Res. 1996;56(11):2497–500. PubMed
Liu Q, et al. MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. Oncogene. 1995;10(3):619–22. PubMed
Simon M, et al. Role of p16 and p14ARF in radio- and chemosensitivity of malignant gliomas. Oncol Rep. 2006;16(1):127–32. PubMed
Iwadate Y, et al. Alteration of CDKN2/p16 in human astrocytic tumors is related with increased susceptibility to antimetabolite anticancer agents. Int J Oncol. 2000;17(3):501–5. PubMed
- Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report
Kevin D. Boyd
Richard S. Houlston
Martin F. Kaiser
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II